Cargando…
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Although there are molecularly distinct subtypes of prostate cancer, no molecular classification system is used clinically. The ribonucleotide reductase small subunit M2 (RRM2) gene plays an oncogenic role in many cancers. Our previous study elucidated comprehensive molecular mechanisms of RRM2 in p...
Autores principales: | Mazzu, Ying Z., Armenia, Joshua, Nandakumar, Subhiksha, Chakraborty, Goutam, Yoshikawa, Yuki, Jehane, Lina E., Lee, Gwo‐Shu Mary, Atiq, Mohammad, Khan, Nabeela, Schultz, Nikolaus, Kantoff, Philip W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400792/ https://www.ncbi.nlm.nih.gov/pubmed/32385899 http://dx.doi.org/10.1002/1878-0261.12706 |
Ejemplares similares
-
Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2019) -
Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2022) -
Increased
MYBL2
expression in aggressive hormone‐sensitive prostate cancer
por: Yoshikawa, Yuki, et al.
Publicado: (2022) -
Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy
por: Wijerathna, Sanath R., et al.
Publicado: (2011) -
Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer
por: Yin, Xin, et al.
Publicado: (2023)